Autologous Decidual-like Natural Killer Cells Therapy for Reproductive Failure
159 participantsStarted 2025-11
Plain-language summary
The aim of this study is to verify the efficacy of in vitro induction of autologous decidual-like NK cells therapy for reproductive failure associated with uterine NK cells abnormalities.
Who can participate
Age range22 Years – 38 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Reproductive failure with abnormal endometrial natural killer (NK) cells in menstrual blood;
* With a clear intention to conceive;
* Normal ovarian function, or premature ovarian insufficiency with ≥2 high-quality cryopreserved embryos available for transfer;
* Endometrial thickness measured by transvaginal ultrasound during the periovulatory period ≥7 mm;
* Body mass index (BMI) between 18 kg/m² and 28 kg/m²;
* Willing to comply with the follow-up plan of this study.
Exclusion Criteria:
* Use of progesterone receptor modulators;
* One of the couple's chromosomal karyotype abnormalities, with no euploid embryo identified via preimplantation genetic testing for aneuploidy;
* Severe endometriosis or adenomyosis, uterine fibroids affecting uterine cavity morphology, uterine malformations, intrauterine adhesions, or thin endometrium;
* Uncontrolled autoimmune or endocrine disorders;
* Contraindications to pregnancy;
* History of malignant tumors;
* Participating in other clinical studies;
* Allergy to blood products.
What they're measuring
1
Ongoing pregnancy rate
Timeframe: 6 months, if a participant is confirmed to get a clinically pregnancy during this period, the follow-up endpoint will be extended until there is a pregnancy outcome
Trial details
NCT IDNCT07230574
SponsorThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School